DOCSLIB.ORG

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes 1 3 CLAUDIA CAVELTI-WEDER, MD HANY ZAYED, PHD (IL-1Ra), was tested in a placebo-controlled 1 4 ANDREA BABIANS-BRUNNER, MD ALAN M. SOLINGER, MD 1 5 study of 70 patients (5). At 13 weeks of CORNELIA KELLER, MD THOMAS MANDRUP-POULSEN, MD, PHD 2 6 treatment, glycated hemoglobin was signif- MARC A. STAHEL, MD CHARLES A. DINARELLO, MD 2 1 icantly improved as a result of enhanced MALAIKA KURZ-LEVIN, MD MARC Y. DONATH, MD b-cell secretory function. Of interest, some improvement promoted by IL-1b blockade lasted for at least 39 weeks follow- OBJECTIVEd b Metabolic activation of the innate immune system governed by interleukin (IL)-1 ing treatment withdrawal (6). More re- contributes to b-cell failure in type 2 diabetes. Gevokizumab is a novel, human-engineered mono- clonal anti–IL-1b antibody. We evaluated the safety and biological activity of gevokizumab in cently, IL-1Ra also was shown to improve patients with type 2 diabetes. insulin secretion in prediabetic patients (7). This indicates the disease-modifying po- RESEARCH DESIGN AND METHODSdIn a placebo-controlled, dose-escalation tential of this therapy (8). study, a total of 98 patients were randomly assigned to placebo (17 subjects) or gevokizumab Although the results obtained with (81 subjects) at increasing doses and dosing schedules. The primary objective of the study was to fi IL-1Ra in patients with type 2 diabetes are evaluate the safety pro le of gevokizumab in type 2 diabetes. The secondary objectives were to assess encouraging, IL-1Ra has characteristics pharmacokinetics for different dose levels, routes of administration, and regimens and to assess that make it unsuitable for the treatment biological activity. of type 2 diabetes, such as its short half-life RESULTSdThe study drug was well tolerated with no serious adverse events. There was one and injection-site reactions (9). It would hypoglycemic event whereupon concomitant insulin treatment had to be reduced. Clearance of have to be taken on a daily basis to maintain gevokizumab was consistent with that for a human IgG2, with a half-life of 22 days. In the adequate suppression of IL-1b. Moreover, combined intermediate-dose group (single doses of 0.03 and 0.1 mg/kg), the mean placebo- the amount of IL-1Ra required would make correcteddecreaseinglycatedhemoglobinwas0.11,0.44,and0.85%after1,2(P =0.017),and3 P treatment an expensive option. Of impor- ( = 0.049) months, respectively, along with enhanced C-peptide secretion, increased insulin tance, an anti–IL-1 strategy that spares sensitivity, and a reduction in C-reactive protein and spontaneous and inducible cytokines. IL-1a may offer safety benefits. Therefore, CONCLUSIONSdThis novel IL-1b–neutralizing antibody improved glycemia, possibly via specifically reducing IL-1b activity with restored insulin production and action, and reduced inflammation in patients with type 2 longer-lasting agents would provide a diabetes. This therapeutic agent may be able to be used on a once-every-month or longer therapeutic improvement in terms of sus- schedule. tained inhibition of IL-1b–mediated islet- associated inflammation. Diabetes Care – 35:1654 1662, 2012 Gevokizumab is a recombinant human- engineered monoclonal antibody that nset of type 2 diabetes occurs when to a pathological activation of the innate binds and neutralizes human IL-1b pancreatic b-cells fail to adapt to the immune system by metabolic stress and is with a Kd of 0.3 pmol/L (10). The predicted O – increased insulin demand caused governed by interleukin (IL)-1 signaling circulating half-life of the antibody was 22 by insulin resistance. Morphological and (1–4). 25 days. The Fc of gevokizumab is the IgG2 therapeutic intervention studies have un- Based on the above-described islet isotype, which unlike IgG1 Fc does not ac- covered an inflammatory process in islets inflammation with a predominant role for tivate the FcRIII on macrophages and other of patients with type 2 diabetes character- IL-1b, we initiated clinical trials of IL-1 myeloid cells, thereby reducing the proba- ized by the presence of cytokines, im- antagonism in type 2 diabetes. In a proof- bility of antibody-dependent cell-mediated mune cells, b-cell apoptosis, amyloid of-concept study, the naturally occurring cytotoxicity. In this study, we evaluated the deposits, and fibrosis.Thisisattributed antagonist of IL-1b,IL-1receptoragonist safety, pharmacokinetics, and diabetes- and inflammation-related parameters of ccccccccccccccccccccccccccccccccccccccccccccccccc gevokizumab in patients with type 2 diabetes. From the 1Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland; the 2Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland; the 3Department of Biostatistics, XOMA, Berkeley, California; the 4Department of Clinical Development, XOMA, Berkeley, RESEARCH DESIGN AND 5 California; the Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, METHODSdThis first-in-humans, and the Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; and the 6Department of Medicine, University of Colorado Denver, Aurora, Colorado. randomized, placebo-controlled, dose- Corresponding author: Marc Y. Donath, [email protected]. escalation study was carried out concur- Received 15 November 2011 and accepted 27 March 2012. rently in the U.S. and Switzerland. The U.S. DOI: 10.2337/dc11-2219. Clinical trial reg. no. NCT00541983, clinicaltrials.gov. arm of the study included 68 subjects (56 A slide set summarizing this article is available online. © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly in the gevokizumab group and 12 in the cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ placebo group) and took place between licenses/by-nc-nd/3.0/ for details. September 2007 and June 2009. The Swiss 1654 DIABETES CARE, VOLUME 35, AUGUST 2012 care.diabetesjournals.org Cavelti-Weder and Associates arm of the study included 30 subjects (25 aminotransferase/alanine aminotransferase intravenous stimulation tests of C-peptide in the gevokizumab group and 5 in the .2 3 upper limit of normal; alkaline phos- release were included. A glucose stimula- placebo group) and took place between phatase .2 3 upper limit of normal; tion test was performed at baseline and at November 2007 and July 2009. XOMA positive test for GAD65 or insulinoma- 4 and 13 weeks to assess b-cell function (U.S.), the manufacturer of gevokizumab, associated protein 2 autoantibodies; and insulin production/reserve. Subjects sponsored the study. known HIV antibody positivity, hepatitis B ingested 75 g glucose and were sampled The eligibility criteria of both arms of surface antigens, and/or hepatitis C anti- for plasma glucose and C-peptide mea- the study were similar. Patients were re- bodies; history or evidence of thyroid abnor- surements at –10, 0, 30, 60, 90, and 120 quested to continue stable doses of baseline malities, including active hyperthyroidism min. Immediately at the end of the oral antidiabetes treatments (metformin, sulfo- needing medication; abnormal T3, T4, glucose tolerance test, an intravenous in- nylureas, and/or insulin) and were asked thyroglobulin, or thyroid-stimulating hor- jection of 0.3 g glucose/kg body wt, 0.5 mg not to change their diet and exercise mone levels; infectious disease (C-reactive glucagon, and 4.5 g arginine was adminis- habits during the study. Both arms of the protein [CRP] .30 mg/L), fever, or infec- tered. Blood then was sampled at 0, 3, 6, 9, study tested single intravenous doses of tion requiring treatment with antibiotics and 12 min. The patients were asked to gevokizumab at the same five-dose levels within 3 weeks; history of recurrent infec- forgo their antidiabetes medication and (0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg). In tion or predisposition to infection; (active fast for 8–9 h prior to the test. Whole- addition, there was a three-part study in the leg or foot ulcer); malignancy within 5 body insulin sensitivity index was calculat- U.S. arm that tested a single intravenous years prior to study entry other than car- ed as 10,000/square root of [fasting glucose dose of 3.0 mg/kg (part 1), a single sub- cinoma in situ of the cervix or adequately (mmol/L) 3 fasting insulin (pmol/L) 3 cutaneous dosing at three dose levels (part treated, nonmetastatic squamous or basal (mean glucose {mmol/L} 3 mean insulin 2), and multiple subcutaneous dosing at two cell carcinoma of the skin; history of severe {pmol/L} during the oral glucose tolerance dose levels (part 3) (Fig. 1A). The follow-up allergic or anaphylactic reactions to human- test)] (12). of patients was 2 months in the U.S. arm and ized or murine monoclonal antibodies; his- 3 months in the Swiss arm. Randomization tory of tuberculosis, positive purified Whole-blood cultures for ex vivo was performed with the use of a common, protein derivative test, or active atopic dis- cytokine production central, computer-generated system with ease requiring medication; asthma; immu- Heparinized blood was obtained before permutated blocks of six schedules. nodeficiency; history or symptoms of a and on days 1, 7, and 28 after the admin- Throughout the course of the study, demyelinating disease; clinically significant istration of gevokizumab. At the same time, treatment assignment was blinded to study diabetic macular edema and/or proliferative blood was sent for routine hematology. A subjects and investigators but not to the diabetic retinopathy by history or fundo- total of 250 mLofbloodwereaddedto sponsor (XOMA). The sponsor maintained scopy; use of a therapeutic monoclonal 1.5-mL sterile cryotubes (Fisher) con- blinding in all communications with inves- antibody within 90 days; participation in taining 750 mL of RPMI (Grand Island) tigators and other site personnel.
Load more

Recommended publications
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Clinical Research in Adult Vasculitis
    Clinical research in adult vasculitis Calgary – October 8th, 2015 Disclosures • Consulting and speaker fees – Hoffmann-La Roche – BMS • Advisory boards – Hoffmann-La Roche – GSK • Educational subventions (CanVasc) – Hoffmann-La Roche – Terumo BCT – Abbott Immunology – BMS – Pfizer-Amgen – Janssen-Cilag – Euroimmun Learning Outcomes 1. To review some of the existing international research networks and groups 2. To review some of the ongoing studies on adult vasculitis, in which Canada participates 3. To discuss issues pertinent to various specialties (internal medicine, rheumatology, nephrology and respirology) including research collaboration in Canada 4. To be aware of CanVasc and its activities in adult vasculitis 2012 revised Chapel hill nomenclature Jennette et al. Arthritis Rheum. 2013 Treatment of severe GPA/MPA CYCLOPHOSPHAMIDE AZATHIOPRINE 2 mg/kg/d 15 mg/kg (d1,14,28 then q3wk) METHOTREXATE 0.3 mg/kg/wk ? LEFLUNOMIDE 20 mg/d 2 mg/kg/d MYCOPHENOLATE MOFETIL 2 g/d Rituximab 500mg q6m RITUXIMAB 375mg/m2 x4 ? + Corticosteroids R 3 - 6 months > 18 months INDUCTION MAINTENANCE + adjuvant/prophylactic measures: cotrimoxazole, osteoporosis treatment, etc DCVAS Study – ACR/EULAR diagnostic and classification criteria for vasculitis – Number of centres: 118 This project anticipates to produce the following: • 1) A new validated set of classification criteria for the primary systemic vasculitides. • 2) A validated set of diagnostic criteria for the primary systemic vasculitides. DCVAS Study • How will the final revisions differ from the current ACR criteria? • The main differences will be: • Use modern diagnostic tests (e.g. ANCA, use of diagnostic ultrasound for GCA), new tools of disease activity (BVAS) and tools measuring vasculitis damage (VDI) to further refine the criteria.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • An Update on the Use of Biologic Therapies in the Management of Uveitis in Behçet’S Disease: a Comprehensive Review Thomas W
    McNally et al. Orphanet Journal of Rare Diseases (2017) 12:130 DOI 10.1186/s13023-017-0681-6 REVIEW Open Access An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review Thomas W. McNally1, Erika M. Damato2,3, Philip I. Murray2,3,4,5, Alastair K. Denniston4,5,6* and Robert J. Barry4,5 Abstract Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes. Keywords: Behçet’s disease, Biologic therapy, Health economics, Immunosuppression, Quality of life, Steroid-sparing agents, Uveitis Background BD occurs throughout all geographic locations, being Behçet’s disease (BD) is a multi-system inflammatory most prevalent and often more severe in countries dis- disorder of unknown aetiology [1, 2].
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Gevokizumab for Chronic Non-Infectious Uveitis
    Horizon Scanning Centre July 2013 Gevokizumab for chronic non- infectious uveitis SUMMARY NIHR HSC ID: 8064 Gevokizumab is an anti-inflammatory humanised IgG2 monoclonal antibody that binds to interleukin-1ß (IL-1ß). It is intended for treatment of chronic, non-infectious uveitis, including that associated with Behҫet’s disease. Binding to IL-1ß blocks the activation of the IL-1 receptor preventing cellular signalling events that produce inflammation. Gevokizumab is intended for monthly subcutaneous (SC) dosing. Uveitis is inflammation of the uveal tract of the eye, which consists of the iris, This briefing is the ciliary body and the choroid. Inflammation of nearby tissues, such as the based on retina, the optic nerve, and the vitreous humour may also occur. Uveitis may information be classified by the anatomical location of the pathology: anterior, available at the time intermediate (vitritis), posterior (retina and choroid) or panuveitis. Chronic of research and a uveitis may be defined as active uveitis that persists longer than three limited literature months. Symptoms of uveitis include: pain, redness, photophobia, search. It is not headaches, visual floaters and decreased visual acuity. Non-infectious intended to be a uveitis may be due to an underlying inflammatory condition, an autoimmune definitive statement disorder or occur as a result of trauma to the eye. In many cases the cause on the safety, remains uncertain. Systemic diseases such as Behҫet’s disease and efficacy or sarcoidosis can be associated with either acute or chronic uveitis. Ocular effectiveness of the involvement is common in Behçet’s disease, and may cause severe uveitis. health technology covered and should The overall incidence of uveitis is estimated to be between 17 and 52.4 per not be used for 100,000 population equating to between 9,500 and 29,200 new cases per commercial year in the UK.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • WO 2018/234879 Al 27 December 2018 (27.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/234879 Al 27 December 2018 (27.12.2018) W !P O PCT (51) International Patent Classification: c/o Novartis Pharmaceuticals Corporation, One Health C07K 16/24 (2006.01) A61K 39/00 (2006.01) Plaza, East Hanover, New Jersey 07936 (US). THUREN, Tom; c/o Novartis Pharmaceuticals Corporation, One (21) International Application Number: Health Plaza, East Hanover, New Jersey 07936 (US). R - PCT/IB20 18/053096 KER, Paul; c/o The Brigham and Women's Hospital, 75 (22) International Filing Date: Francis Street, Boston, Massachusetts 021 15 (US). LIB- 03 May 2018 (03.05.2018) BY, Peter; c/o The Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 021 15 (US). OT- (25) Filing Language: English TEWELL, Penelope; c/o The Medical School, Beech Hill (26) Publication Langi English Road, Sheffield South Yorkshire S10 2RX (GB). LAU, Yi Yang; c/o Novartis Pharmaceuticals Corporation, One (30) Priority Data: Health Plaza, East Hanover, New Jersey 07936 (US). 62/523,458 22 June 2017 (22.06.2017) US DUGAN, Margaret; c/o Novartis Pharmaceuticals Corpo 62/529,5 15 07 July 2017 (07.07.2017) US ration, One Health Plaza, East Hanover, New Jersey 07936 62/550,307 25 August 2017 (25.08.2017) US (US). 62/550,325 25 August 2017 (25.08.2017) US 62/596,054 07 December 20 17 (07. 12.20 17) US (81) Designated States (unless otherwise indicated, for every 62/649,63 1 29 March 2018 (29.03.2018) US kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 4056 Basel (CH).
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]